Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Likely To Launch In-House Actiq Generic To Compete With Barr

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon is planning to launch an in-house generic version of Actiq (transmucosal fentanyl) to compete with Barr, the company said

You may also be interested in...



See You In September: Cephalon Anticipates Generic Actiq Ahead Of Fentora Follow-On

Barr reports plans to begin selling a generic version of the pain drug in the second half of September.

See You In September: Cephalon Anticipates Generic Actiq Ahead Of Fentora Follow-On

Barr reports plans to begin selling a generic version of the pain drug in the second half of September.

Cephalon Anticipates Fentora Launch In Q4

Company also looking at 2007 launch for Nuvigil.

Related Content

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel